Rakovina Therapeutics Inc. (RKV.V)
| Previous close | 0.0900 |
| Open | 0.0900 |
| Bid | 0.0900 x N/A |
| Ask | 0.0900 x N/A |
| Day's range | 0.0900 - 0.0900 |
| 52-week range | 0.0050 - 0.1600 |
| Volume | |
| Avg. volume | 72,930 |
| Market cap | 6.285M |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings date | 27 Apr 2024 - 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireRakovina Therapeutics Presented at American Association of Cancer Research Annual Meeting at the San Diego Convention Center Today
VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage response inhibitor therapeutics, is pleased to announce that members of the Company’s scientific team presented new data on the Company’s novel kt-3000 series at the American Association of Cancer Research (AACR) Annual Meeting at the San D
- GlobeNewswire
Rakovina Therapeutics To Host Informational Webinar on April 3, 2024
Announces Capital Markets Advisory AgreementVANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina Therapeutics” or the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage response inhibitor therapeutics, will be hosting an informational webinar on Wednesday, April 3, 2024. The Rakovina leadership team and members of the scientific team will host the co
- GlobeNewswire
Rakovina Therapeutics Announces Strategic Pivot to AI
Company Leveraging Deep Docking AI Drug Discovery PlatformVANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage response inhibitor therapeutics, is pleased to announce a strategic evolution in its business model that will place the Company at the forefront of artificial intelligence-driven (AI
